RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - EFFETTI MOLECOLARI PLEIOTROPI DELLA INIBIZIONE DELLA PDE5
• 2 - La cardiotossicità da terapia anti-neoplastica coinvolge le cellule staminali e progenitori miocardici residenti
• 3 - Effetti clinici e molecolari dell'eccesso di glucocorticoidi
• 4 - Studio degli effetti genomici dell'aldosterone in modelli cellulari ed in vivo.
• 5 - Determinanti genetici e molecolari del ruolo della COX-2 nell'aterotrombosi.
• 6 - Modulazione farmacologica della chemioterapia antitumorale
• 7 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 8 - RUOLO DEI MECCANISMI DI SEGNALE CELLULARE E DELLE SPECIE REATTIVE DELL'OSSIGENO E DELL'AZOTO NELL'INVECCHIAMENTO CELLULARE E NELLA CRESCITA NEOPLASTICA.
• 9 - Ruolo fisiopatologico di poli(ADPR)polimerasi (PARP) e sue implicazioni terapeutiche.
• 10 - Studio delle basi molecolari e cellulari della risposta alla terapia mirata con inibitori delle tirosin-kinasi per l'ottimizzazione del trattamento delle leucemia Philadelphia positive

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA CLINICA
  • ENDOCRINOLOGIA

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
    • THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Classificazione geografica

• Regione: Lazio

Bibliografia

Reference List

1. Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11(2):214-222.
2. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003; 58(5):632-638.
3. Filippi S, Amerini S, Maggi M, Natali A, Ledda F. Studies on the mechanisms involved in the ATP-induced relaxation in human and rabbit corpus cavernosum. J Urol 1999; 161(1):326-331.
4. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75(4):725-748.
5. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis: ESSENTIAL ROLE OF NITRIC OXIDE SIGNALING. J Biol Chem 2005; 280(13):12944-12955.
6. Iacobellis G, Cipriani R, Gabriele A, Di Mario U, Morano S. High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients. Cytokine 2004; 27(1):25-30.
7. Sauzeau V, Le Jeune H, Cario-Toumaniantz C et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000; 275(28):21722-21729.
8. Loirand G, Rolli-Derkinderen M, Pacaud P. RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 2005; 288(3):H1051-H1056.
9. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389(6654):990-994.
10. Morelli A, Filippi S, Mancina R et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145(5):2253-2263.
11. Kukreja RC, Ockaili R, Salloum F et al. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. J Mol Cell Cardiol 2004; 36(2):165-173.
12. Sheth A, Park JE, Ong YE, Ho TB, Madden BP. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul Pharmacol 2005; 42(2):41-45.
13. Carosa E, Martini P, Brandetti F et al. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004; 61(3):382-386.
14. Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917):868-874.
15. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37(4):1053-1059.
16. Kawata H, Yoshida K, Kawamoto A et al. Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C epsilon in the rat ischemic myocardium. Circ Res 2001; 88(7):696-704.
17. Namiki A, Brogi E, Kearney M et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 1995; 270(52):31189-31195.
18. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 2005; 111(6):742-746.
19. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 2003; 59(2):441-449.
20. Corona G, Mannucci E, Mansani R et al. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 2004; 46(2):222-228.
21. Bonetti PO, Lerman LO,Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J 2003; 24(3):225-248.
22. Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004; 498(1-3):189-194.
23. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103(1):113-118.
24. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273(37):24266-24271.
25. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21(11):1712-1719.
26. Tantini B, Manes A, Fiumana E et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100(2):131-138.
27. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001; 56(6):702-708.
28. Isidori AM, Caprio M, Strollo F et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84(10):3673-3680.
29. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10(4):493-496.
30. Liu PY, Christian RC, Ruan M, Miller VM, Fitzpatrick LA. Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J Clin Endocrinol Metab 2005; 90(2):1041-1046.
31. Simpson ER, Mahendroo MS, Means GD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994; 15(3):342-355.
32. Phillips GB. Evidence for hyperestrogenemia as the link between diabetes mellitus and myocardial infarction. Am J Med 1984; 76(6):1041-1048.
33. Phillips GB. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism 1993; 42(1):116-120.
34. Wang Y, Sudilovsky D, Zhang B et al. A human prostatic epithelial model of hormonal carcinogenesis. Cancer Res 2001; 61(16):6064-6072.
35. Sebastian S, Bulun SE. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J Clin Endocrinol Metab 2001; 86(10):4600-4602.
36. Simpson ER, Clyne C, Rubin G et al. Aromatase--a brief overview. Annu Rev Physiol 2002; 64:93-127.
37. Simpson ER. Role of aromatase in sex steroid action. J Mol Endocrinol 2000; 25(2):149-156.
38. Jannini EA, Lombardo F, Salacone P, Gandini L, Lenzi A. Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate. Fertil Steril 2004; 81(3):705-707.
39. Slattery MM, Brennan C, O'Leary MJ, Morrison JJ. Human chorionic gonadotrophin inhibition of pregnant human myometrial contractility. BJOG 2001; 108(7):704-708.
40. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod 2000; 15(4):806-809.
41. Zuo J, Lei ZM, Rao CV. Human myometrial chorionic gonadotropin/luteinizing hormone receptors in preterm and term deliveries. J Clin Endocrinol Metab 1994; 79(3):907-911.

Parole Chiave

ANDROLOGIA; DISFUNZIONE ERETTILE; TESTICOLO; DIABETE MELLITO; RIPRODUZIONE; INIBITORI FOSFODIESTERASI TIPO 5; ENDOCRINOLOGIA DELL'UTERO; TESTOSTERONE; AROMATASI